Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548217 | 0.73 | ALDH1A1 (0.40) | CAMKK1CAMKK2DRD4DRD3ALDH1A1 | |
| SCHEMBL29549122 | 0.73 | CAMKK1 (0.38) | CAMKK1CAMKK2DRD4DRD3PDE1A | |
| SCHEMBL14849720 | 0.71 | TRPV1 (0.38) | PDE1APDE1BPDE1CTYK2 | |
| SCHEMBL29548203 | 0.68 | CAMKK1 (0.38) | CAMKK1CAMKK2DRD4DRD3ALDH1A1 | |
| SCHEMBL29548233 | 0.67 | CAMKK1 (0.36) | CAMKK1CAMKK2DRD4DRD3PDE1A | |
| SCHEMBL14685880 | 0.67 | TP53 (0.47) | PDE10A | |
| SCHEMBL14849672 | 0.67 | HTR2C (0.49) | KDM4EPDE10A | |
| SCHEMBL29548929 | 0.67 | DRD4 (0.39) | CAMKK1CAMKK2DRD4DRD3ALDH1A1 | |
| SCHEMBL1160605 | 0.66 | JAK1 (0.54) | PDE1APDE1BPDE1CJAK2JAK1 | |
| SCHEMBL14849768 | 0.66 | SLC18A3 (0.42) | DRD4DRD3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | ALMANSA ROSALES CARMEN (ES) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | CAMKK1 1476/4885CAMKK2 1272/4885DRD4 3367/4885 |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | CAMKK1 1476/4885CAMKK2 1272/4885DRD4 3367/4885 |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | CAMKK1 1476/4885CAMKK2 1272/4885DRD4 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.